November 2022

In Canada, nearly a quarter of the adult population reported having consumed cannabis in the last 12 months in 2021. Cannabis use is considered to be fairly safe in most cases (Fischer et al., 2021). In Quebec, nearly half of the population aged 15 years and older would have experimented with cannabis use at least once in their lifetime.

The psychoactive effects of cannabis sought by consumers are mainly attributable to a specific molecule produced by the plant, namely tetrahydrocannabinol (THC). This molecule belongs to a class of compounds numbering in the dozens and called “cannabinoids”. Content in cannabinoids and their respective concentrations can vary greatly between different cannabis plants and across diverse horticultural practices. Cannabidiol (CBD), on the other hand, is a so-called “non-psychoactive” cannabinoid, meaning that it does not provide any euphoric effect to consumers. CBD products are currently growing in popularity among the general population, as they are often advertised and promoted for their potential physiological effects that may be beneficial. Studies on the effects of cannabinoids in humans have so far focused mainly on THC. On the other hand, studies on the behavioral effects of CBD have tested mostly high doses. It is therefore essential to study, in a controlled environment, the effects of CBD administration at lower doses, such as those currently available on the recreational market in Canada and the United States. The laboratory is thus currently conducting a randomized controlled trial on the effect of CBD when consumed orally (CBD-ingested). A second similar project will also be conducted on the effects of CBD when administered by the respiratory tract (CBD-inhaled).

For more information about the recruitment of our studies, please consult this link.

The participants we are looking for must meet the following criteria:

  • Person in good health
  • Occasional cannabis user